Brought to you by 
Amylin enters CNS field through JV with PsychoGenics
02 Feb 2007
Executive Summary
PsychoGenics (CNS drug target validation and compound selection) and metabolic disease company Amylin Pharmaceuticals have created the 50-50 joint venture Psylin Neurosciences and equally participated in the start-up's Series A round.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
-
Drug Discovery Tools
- Molecular Diversity
Deal Status
- Final
Deal Type
-
Alliance
- Intra-Biotech Deal
- Joint Venture
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Amylin enters CNS field through JV with PsychoGenics
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice